Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Affimed Ord Shs (NQ: AFMD )

0.6609 -0.0408 (-5.81%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,185,867
Open 0.6500
Bid (Size) 0.6400 (50)
Ask (Size) 0.6900 (20)
Prev. Close 0.7017
Today's Range 0.5502 - 0.6910
52wk Range 0.5502 - 5.100
Shares Outstanding 149,339,335
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Earnings Scheduled For March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. 
Via Benzinga
Affimed Reports 2022 Financial Results and Operational Progress
From Affimed N.V.
Via Globe NewsWire

Performance

YTD
-45.38%
-45.38%
1 Month
-31.65%
-31.65%
3 Month
-43.03%
-43.03%
6 Month
-66.95%
-66.95%
1 Year
-85.08%
-85.08%

More News

Read More
Earnings Preview For Affimed
Via Benzinga
Analyst Ratings for Affimed
Via Benzinga
4 Analysts Have This to Say About Affimed
Via Benzinga
Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023
From Affimed N.V.
Via Globe NewsWire
Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for
From Affimed N.V.
Via Globe NewsWire
AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery
From Affimed N.V.
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference
From Affimed N.V.
Via Globe NewsWire
AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target
From Affimed N.V.
Via Globe NewsWire
Affimed to Present at the SVB Securities 2023 Global Biopharma Conference
From Affimed N.V.
Via Globe NewsWire
Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13
From Affimed N.V.
Via Globe NewsWire
Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia
From Affimed N.V.
Via Globe NewsWire
Dow Surges Over 250 Points; Weber Shares Spike Higher
Via Benzinga
Analyst Says Affimed's 'Innate Cell Engagers Like No Others,' Sees Mammoth Upside
Via Benzinga
Crude Oil Rises Sharply; Adicet Bio Shares Plunge
Via Benzinga
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
Via Benzinga
Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH
From Affimed N.V.
Via Globe NewsWire
US Stocks Higher; Dow Rises Over 100 Points
Via Benzinga
Citing Lack Of Durability, Affimed Scraps AFM13 Monotherapy Plans For NK Cell Combo
Via Benzinga
Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
From Affimed N.V.
Via Globe NewsWire
Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting
From Affimed N.V.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.